MRA Advisory Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$220K Buy
9,129
+391
+4% +$10.2K 0.08% 132
2026
Q1
$245K Buy
8,738
+269
+3% +$7.16K 0.1% 116
2025
Q4
$211K Sell
8,469
-10
-0.1% -$252 0.09% 116
2025
Q3
$216K Buy
+8,479
New +$209K 0.09% 121
2025
Q2
Sell
-9,762
Closed -$247K 155
2025
Q1
$247K Sell
9,762
-5,438
-36% -$142K 0.13% 100
2024
Q4
$403K Sell
15,200
-6,940
-31% -$188K 0.21% 57
2024
Q3
$641K Sell
22,140
-140
-0.6% -$4.08K 0.35% 37
2024
Q2
$623K Buy
22,280
+3,970
+22% +$109K 0.36% 34
2024
Q1
$508K Buy
18,310
+2,132
+13% +$59.2K 0.3% 46
2023
Q4
$466K Sell
16,178
-639
-4% -$19.3K 0.31% 48
2023
Q3
$558K Sell
16,817
-3,024
-15% -$107K 0.4% 51
2023
Q2
$728K Buy
19,841
+461
+2% +$17.9K 0.5% 35
2023
Q1
$791K Buy
19,380
+2,697
+16% +$116K 0.57% 31
2022
Q4
$855K Buy
16,683
+476
+3% +$22.8K 0.67% 31
2022
Q3
$677K Buy
16,207
+141
+0.9% +$6.85K 0.58% 33
2022
Q2
$842K Sell
16,066
-4,314
-21% -$220K 0.74% 27
2022
Q1
$1.05M Buy
20,380
+1,151
+6% +$59.7K 0.8% 26
2021
Q4
$1.14M Sell
19,229
-242
-1% -$12K 0.88% 29
2021
Q3
$837K Buy
19,471
+596
+3% +$26.4K 0.71% 34
2021
Q2
$739K Buy
18,875
+1,656
+10% +$64.4K 0.63% 37
2021
Q1
$624K Buy
17,219
+606
+4% +$21.5K 0.59% 41
2020
Q4
$612K Buy
+16,613
New +$609K 0.6% 40

Other funds holding PFE

MRA Advisory Group's PFE Position: Q2 2026 in Review

MRA Advisory Group increased its Pfizer (PFE) stake by 4.5% in Q2 2026, buying an estimated $10.2K and bringing the position to 9,129 shares worth $220K. The position accounts for 0.08% of the portfolio, ranked #132.

MRA Advisory Group first reported a position in PFE in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.14M in Q4 2021. 900 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • MRA Advisory Group held 9,129 shares of Pfizer worth $220K as of Q2 2026.
  • MRA Advisory Group bought 391 Pfizer shares in Q2 2026, an estimated $10.2K.
  • Pfizer made up 0.08% of MRA Advisory Group's portfolio in Q2 2026, its #132 holding.
  • MRA Advisory Group first reported a position in Pfizer in Q4 2020 and has held it in 22 quarters since.
  • MRA Advisory Group's Pfizer position peaked at $1.14M in Q4 2021.
  • 900 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on MRA Advisory Group's 13F filing for Q2 2026, filed 8 Jul 2026.